

# Dimezeft 1GM Injection

## Ceftazidime (1g) Injection: Information Guide

### Description

Ceftazidime is a third-generation cephalosporin antibiotic with broad-spectrum activity against Gram-negative and some Gram-positive bacteria. It is particularly effective against *Pseudomonas aeruginosa* and is used in treating severe bacterial infections.

---

### Composition

- **Active Ingredient:** Ceftazidime (1g as ceftazidime pentahydrate).
  - **Dosage Form:** Sterile powder for injection.
- 

### Indications

Ceftazidime is indicated for the treatment of the following infections:

- Respiratory tract infections, including pneumonia.
  - Urinary tract infections.
  - Skin and soft tissue infections.
  - Bone and joint infections.
  - Intra-abdominal infections, including peritonitis.
  - Septicemia.
  - Meningitis caused by susceptible organisms.
  - Infections in neutropenic patients.
- 

## Dosage and Administration

### Route of Administration:

- Intravenous (IV) or intramuscular (IM) injection.

### Dosage:

- **Adults and children over 12 years:** Usual dose: 1g every 8 hours. For severe infections, 2g every 8 hours.
  - **Children (over 1 month):** 30–50 mg/kg every 8 hours, not exceeding 6g/day.
  - **Neonates:** 25–60 mg/kg/day in divided doses.
  - **Renal Impairment:** Dosage adjustment is necessary based on creatinine clearance.
- 

### Reconstitution

- **Intravenous Use:** Dissolve 1g vial in 10mL of sterile water for injection.
  - **Intramuscular Use:** Dissolve 1g vial in 3mL of sterile water for injection.
  - Shake well until completely dissolved.
- 

### Contraindications

- Hypersensitivity to ceftazidime, cephalosporins, or any beta-lactam antibiotics.
- 

## Warnings and Precautions

- **Use with caution in patients with a history of severe hypersensitivity to penicillins or other beta-lactam drugs.**
  - **Monitor renal function in patients with renal impairment.**
  - **Overgrowth of non-susceptible organisms (e.g., fungi) may occur with prolonged use.**
- 

**Note: This is a prescription medication. Use only under the guidance of a qualified healthcare professional.**

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,  
Panchkula-134113

TM: Trademark Applied for

## Adverse Effects

- **Common: Diarrhea, nausea, injection site reactions, rash.**
  - **Serious: Anaphylaxis, Clostridium difficile-associated diarrhea, seizures (in renal impairment), and hematologic abnormalities.**
- 

## Storage

- **Store in a cool, dry place below 25°C.**
  - **Reconstituted solution should be used immediately or stored as per manufacturer's instructions.**
- 

## Pharmacokinetics

- **Absorption: Not orally absorbed; administered parenterally.**
  - **Distribution: Widely distributed, including penetration into cerebrospinal fluid.**
  - **Elimination: Primarily excreted unchanged via the kidneys.**
-